This article is more than 5 years old. Information may no longer be current.

FDA clears interoperable insulin pump, nonhormonal drug reduces hot flashes – top stories in endocrinology

The FDA cleared a second interoperable insulin pump for use in an automated insulin delivery system, and a nonhormonal drug compound was associated with fewer hot flashes and lower symptom severity in menopausal women.

These and more were among the most popular stories in endocrinology last week.

FDA clears second interoperable insulin pump

The FDA cleared Insult to market its tubeless Omnipod DASH Insulin Management System as an integrated insulin pump, allowing it to be part of an interoperable, automated insulin delivery system, according to an industry statement released last week. Read more.

Nonhormonal drug reduces hot flash severity, symptoms in menopause

Menopausal women experiencing moderate to severe vasomotor symptoms randomly assigned to an oral, nonhormonal compound for 12 weeks experienced fewer weekly hot flashes and reduced symptom severity across doses compared with similar women assigned placebo, according to findings presented at the North American Menopause Society annual meeting. Read more.

Frequent hot flashes may signal increased CV risk

Women early in the menopause transition who reported experiencing at least six hot flashes per 2 weeks were 62% more likely to experience a cardiovascular event during 20 years of follow-up when compared with similar women who reported no hot flashes, according to an analysis of the Study of Women’s Health Across the Nation presented at the North American Menopause Society annual meeting. Read more.

Novel liver-targeted insulin comparable to insulin lispro in type 1 diabetes

Adults with type 1 diabetes assigned to a mealtime, liver-targeted insulin using hepatocyte-directed vesicle technology for 6 months experienced a similar reduction in HbA1c when compared with similar adults assigned to insulin lispro, according to findings published in Diabetes Care. Read more.

New VITAL analyses shed light on vitamin D for bone health, fall prevention

Debate continues among endocrinologists regarding what constitutes the “optimal” level of vitamin D, and dozens of studies have assessed the benefits of vitamin D supplementation on everything from fracture risk to diabetes and autoimmune disease. Read more.